Triplet chemotherapy with or without bevacizumab as first line treatment for metastatic colorectal cancer: An AGEO multicenter real-world study.
R VarnierC ToullecS PhilonenkoA DupréP ArtruE HafligerA DrouillardC TorregrosaS PernotP McLellanT LecomteV MoulinC LécailleY TouchefeuC LocherJ TaiebC CoutzacPublished in: Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver (2024)
This study highlights several factors influencing Tri-CT use +/- bevacizumab decision and confirms the real-world good oncological outcomes and tolerability of these regimens in mCRC patients. Our results suggest that Tri-CT alone may by an appropriate option for specific subgroups of patients.
Keyphrases
- end stage renal disease
- metastatic colorectal cancer
- newly diagnosed
- ejection fraction
- chronic kidney disease
- computed tomography
- peritoneal dialysis
- prognostic factors
- squamous cell carcinoma
- magnetic resonance imaging
- prostate cancer
- randomized controlled trial
- type diabetes
- adipose tissue
- open label
- radiation therapy
- dual energy
- patient reported outcomes
- skeletal muscle
- insulin resistance
- double blind
- radical prostatectomy
- decision making